AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tonyt who wrote (390)	8/16/1997 8:28:00 AM
From: tonyt	of 2173

Dow Jones: SAN DIEGO -(Dow Jones)- Amylin Pharmaceuticals Inc. said its drug aimed at improving glucose regulation for insulin dependent diabetics was effective in an advanced stage clinical trial. The drug, pramlintide, is a synthetic version of the human hormone amylin, which is deficient in patients with diabetes who use insulin. Amlyin said pramlintide improved glucose control without increased risk of hypoglycemia and improved weight control and cholesterol profiles in patients with type 1 diabetes. Amlyin said in another study, the lowering of glucose in two of the three pramlintide dose groups achieved statistical significance after six months but not after 12 months. The company said both studies were double blind and placebo controlled and conducted for a 12-month treatment period. The type 1 diabetes study involved 477 patients, and the dosing regimen was 30 micrograms four-times daily, with certain patients escalating to 60 micrograms at 20 weeks. The type 2 diabetes study involved 539 patients, and the dosing regimens were 30 micrograms, 75 micrograms and 150 micrograms three-times daily. Copyright (c) 1997 Dow Jones & Company, Inc. All Rights Reserved.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next